agsandrew-shutterstock-com-1

agsandrew / Shutterstock.com

9 April 2015Genetics

The CRISPR patent war

Research into genome-editing technologies has progressed to a point where we can read the strains of DNA that exist in almost every cell of our bodies as if they were on a word processor and take faulty, disease-causing genes out of a sequence and replace them with functioning ones.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Why CRISPR may define pre- and post-AIA changes

17 September 2015 Many players are piling into the scrum surrounding the patent eligibility of CRISPR technology. Mercedes Meyer of Drinker Biddle & Reath discusses the legal implications of CRISPR as a potential groundbreaking foundation technology.

USPTO ignites CRISPR/Cas9 patent battle

13 January 2016 Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.

More on this story

Why CRISPR may define pre- and post-AIA changes

17 September 2015 Many players are piling into the scrum surrounding the patent eligibility of CRISPR technology. Mercedes Meyer of Drinker Biddle & Reath discusses the legal implications of CRISPR as a potential groundbreaking foundation technology.

USPTO ignites CRISPR/Cas9 patent battle

13 January 2016 Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.

More on this story

Why CRISPR may define pre- and post-AIA changes

17 September 2015 Many players are piling into the scrum surrounding the patent eligibility of CRISPR technology. Mercedes Meyer of Drinker Biddle & Reath discusses the legal implications of CRISPR as a potential groundbreaking foundation technology.

USPTO ignites CRISPR/Cas9 patent battle

13 January 2016 Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.

More features

GSK triumphs in EPO appeal, revoking Pfizer patent

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

LSPN Fall: Gilead GC shares top drafting tips

How post-filing data rescued Novo Nordisk’s Ozempic patent in China

How to navigate patent term adjustment in China

Preventative IP for preventative pharma healthcare

Dexcom suffers second patent revocation at hands of UPC